|
Daily Medical Update
Hyperaldosteronism
Tuesday, April 14, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Hypertension (2025) - Meta-analysis
Key Findings
- Adrenalectomy achieved greater reduction in indexed left ventricular mass versus mineralocorticoid receptor antagonist therapy.
- Both strategies improved blood pressure, but surgery produced larger improvement in cardiac structural remodeling.
📋 Practice Implication: Refer eligible unilateral primary aldosteronism patients for adrenalectomy when cardiac remodeling reversal is a major treatment goal.
|
American Journal of Hypertension (2025) - Systematic review and network meta-analysis
Key Findings
- Adrenalectomy and percutaneous adrenal ablation showed superior systolic blood pressure reduction versus mineralocorticoid receptor antagonists.
- Both procedural approaches improved serum potassium and aldosterone-to-renin ratio more than medical therapy.
📋 Practice Implication: Use percutaneous adrenal ablation as a fallback pathway for unilateral disease when surgery is not feasible and medical therapy is insufficient.
|
Journal of Clinical Hypertension (2025) - Systematic review and meta-analysis
Key Findings
- Super-selective adrenal artery embolization reduced systolic blood pressure by about 19.8 mmHg.
- The procedure improved aldosterone excess and normalized serum potassium with favorable short-term safety outcomes.
📋 Practice Implication: Consider embolization for unilateral primary aldosteronism in patients who need a minimally invasive option but still require biochemical improvement.
|
The Lancet Diabetes & Endocrinology (2025) - Systematic review and meta-analysis
Key Findings
- Unsuppressed post-treatment renin was associated with lower cardiovascular event risk, with a pooled hazard ratio of 0.43 versus persistently suppressed renin.
- After 5 or more years of follow-up, unsuppressed renin remained associated with lower cardiovascular events, with a pooled hazard ratio of 0.33.
📋 Practice Implication: Titrate mineralocorticoid receptor antagonist therapy to achieve renin unsuppression rather than relying on blood pressure control alone.
|
European Journal of Nuclear Medicine and Molecular Imaging (2025) - Systematic review and meta-analysis
Key Findings
- CXCR4-targeted PET-CT improved subtype localization and lateralization performance versus standard noninvasive assessment alone.
- Imaging results correlated with postoperative blood pressure improvement and reduced dependence on adrenal venous sampling in selected cases.
📋 Practice Implication: Use CXCR4-targeted PET/CT to strengthen subtype localization when adrenal venous sampling is unavailable, unsuccessful, or high risk.
|
|
Recent evidence in primary aldosteronism continues to favor definitive treatment for unilateral disease, with adrenalectomy providing stronger blood pressure, biochemical, and cardiac remodeling benefits than medical therapy alone. Newer minimally invasive options such as percutaneous ablation and super-selective adrenal artery embolization show intermediate benefit for selected nonoperative patients, while medically treated patients appear to have better long-term cardiovascular outcomes when renin is no longer suppressed. Functional imaging with CXCR4-targeted PET/CT also shows improving accuracy for subtype localization when adrenal venous sampling is difficult or unavailable.
|
|